eMC - trusted, up to date and comprehensive information about medicines
Link to eMC medicine guides website
eMC homepage
Get Medicines Compendium UK app here

Bristol Myers Squibb-AstraZeneca EEIG

Bristol-Myers Squibb House, Uxbridge Business Park, Sanderson Road, Uxbridge, Middlesex, UB8 1DH, UK
Telephone: +44(0)1895523010
Fax: +44(0)1895523010
E-mail: medical.information@bms.com
Medical Information Direct Line: +44(0)8007311736
Medical Information Fax: +44(0)1895523677

Before you contact this company: often several companies will market medicines with the same active ingredient. Please check that this is the correct company before contacting them. Why?

Patient Information Leaflet last updated on the eMC: 11/01/2012
PIL Onglyza 2.5mg & 5mg film-coated tablets

When a pharmaceutical company changes an SPC or PIL, a new version is published on the eMC. For each version, we show the dates it was published on the eMC and the reasons for change.

Updated on 11/01/2012 and displayed until Current
Reasons for adding or updating:
  • Change to warnings or special precautions for use
  • Change to side-effects
  • Change to date of revision
Updated on 30/11/2011 and displayed until 11/01/2012
Reasons for adding or updating:
  • Change to, or new, use for medicine
  • Change to date of revision
  • Change to warnings or special precautions for use
Updated on 08/11/2011 and displayed until 30/11/2011
Reasons for adding or updating:
  • Change to date of revision
  • Change of contra-indications
  • Change to side-effects
Updated on 15/03/2011 and displayed until 08/11/2011
Reasons for adding or updating:
  • Correction of spelling/typing errors
Updated on 04/03/2011 and displayed until 15/03/2011
Reasons for adding or updating:
  • Change of inactive ingredient
  • Change to packaging
  • Change to how the medicine works
  • Change to date of revision
  • Addition of joint PIL covering all presentations
  • Change to, or new, use for medicine
  • Change to warnings or special precautions for use
  • Change to side-effects
  • Change to information about driving or using machinery
  • Change to Marketing Authorisation Holder
  • Change to dosage and administration
Updated on 22/07/2010 and displayed until 04/03/2011
Reasons for adding or updating:
  • Change to MA holder contact details
Updated on 06/10/2009 and displayed until 22/07/2010
Reasons for adding or updating:
  • New PIL for new product

Active Ingredients/Generics

 
   saxagliptin hydrochloride